Big news for budgets

Finally – biosimilar competition for Humira (adalimumab) is coming

Adalimumab (Humira) is the largest biologic to face biosimilar competition with 2021 U.S. sales of $20.7B. The introduction of biosimilars (seven approved, more on the way) heralds tremendous budget savings and competitive success for our members. Read more in Vizient’s latest forecast.

0.00
%

Projected overall drug price inflation rate for Jan. 1 – Dec. 31, 2023

Gain access now

Download the latest drug budget forecasts and market insights to prepare your 2023 pharmaceutical budget.

This report contains data you can put into action.

Access the report

Pharmacy program participants

Enjoy exclusive access to companion resources and additional information

View price change projections at the individual medication level by generic drug name and by therapeutic class.

Read now
An excerpt from the Pharmacy Market Outlook, this document provides highlights from the complete report.

Learn more
This communication describes the most consequential issues confronting pharmacy while determining the greatest opportunities to accelerate growth as well as provide better patient access and outcomes from the significant investment you place in pharmaceuticals.

Read now
An excerpt from the Pharmacy Market Outlook, this document shows the forecasted timetable for new drug approvals, regulatory and accreditation events, and the anticipated availability of new generics and biosimilars.

Learn more
Access the Drug Budget Forecast to apply the projections in the Pharmacy Market Outlook to your unique purchasing patterns and develop your plan for 2023. This tool is available in the Vizient Savings Actualyzer for Pharmacy platform.

Access now
How to use - Provides an overview on how to best utilize and optimize the Drug Budget Forecast reporting solution
While plasma donations have been increasing again after the pandemic, some challenges will likely continue to affect plasma supply. Track the economics of plasma and access additional resources.

Access now
Steven Lucio, PharmD, Vizient Senior Principal, shares his expertise about biosimilars and their use. A particularly hot topic in pharmacy right now!

Learn more
Financial leaders webinar
During this webinar, pharmacy experts discussed the financial impact of the evolving healthcare landscape and provided expert insights from our summer 2022 Pharmacy Market Outlook.
Watch video
View the presentation

Join us for the summer 2022 Pharmacy Market Outlook webinar series
As a follow-up to our summer 2022 release, join us as for two informational webinars on hot topics and trends covered in this edition:
  • Cardiology clinic management in the era of new medications
    During this webinar, we will examine the changes in the cardiology medication guidelines and new entrants.
    Sep. 14, 1 p.m. CT
  • Operationalizing biosimilars in the ambulatory space
    During this webinar, pharmacy experts will discuss how organizations can begin now to get policies and practices aligned at hospitals in order to adopt biosimilar adalimumab.
    Oct. 12, 1 p.m. CT

There is no limit to the challenges and opportunities facing pharmacy practice over the next six to 18 months.

Steven Lucio, PharmD, BCPS

Sr. Principal, Vizient Center for Pharmacy Practice Excellence